Why the FDA’s Moderna Decision Sets a Dangerous Precedent

Описание: The FDA recently pushed back on Moderna’s application for an mRNA-based influenza vaccine—but not because the vaccine failed.

Instead, the FDA objected to the comparator Moderna used in its clinical trial, despite the fact that this comparator had been previously discussed and accepted during the trial’s design phase.

In this video, infectious disease physician Dr. Amesh Adalja explains why this decision matters far beyond a single company or vaccine. When regulatory standards change mid-process, it introduces unpredictability that can discourage innovation, deter investment, and slow the development of next-generation medical technologies.

If companies can’t rely on transparent, stable regulatory pathways, the incentive to spend years—and billions of dollars—developing new vaccines starts to disappear.

This video explores:

Why trial comparators matter in FDA approval
How regulatory unpredictability affects biotech investment
The broader implications for mRNA vaccine development
Why this decision sets a troubling precedent
This isn’t about Moderna alone—it’s about how regulation shapes the future of vaccine innovation.

If you’re interested in public health, science policy, and how regulation affects medical innovation, consider subscribing for more expert analysis.